SEC Form SC 13G/A filed

2/16/21 12:23:54 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CARA alert in real time by email

SC 13G/A 1 cara13gadec20.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Cara Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 140755109 (CUSIP NUMBER) December 31, 2020 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 355,830 6. Shared Voting Power* 0 7. Sole Dispositive Power* 2,429,235 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,429,235 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 4.8% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: Cara Therapeutics, Inc. Item 1(b) Address of Issuer's Principal Executive Offices: 4 STAMFORD PLAZA, 107 ELM STREET 9TH FLOOR, STAMFORD, CONNECTICUT 06902 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. ("Price Associates") Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 140755109 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 16, 2021 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2020

Get the next $CARA alert in real time by email

Recent Analyst Ratings for

$CARA

Date	Price Target	Rating	Analyst
6/13/2024	$6.00 → $1.00	Buy → Hold	Stifel
6/13/2024	$10.00 → $1.00	Buy → Hold	Canaccord Genuity
6/13/2024		Buy → Hold	Needham
6/13/2024		Buy → Neutral	H.C. Wainwright
3/8/2023	$13.00 → $6.00	Neutral → Underperform	BofA Securities
3/8/2022	$17.00 → $20.00	Neutral → Overweight	JP Morgan
11/1/2021	$33.00	Buy	Canaccord Genuity
8/24/2021	$33.00 → $35.00	Buy	HC Wainwright & Co.

More analyst ratings

SEC Form SC 13G/A filed

2/16/21 12:23:54 PM ET

$CARA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CARA alert in real time by email

Recent Analyst Ratings for

$CARA

Date	Price Target	Rating	Analyst
6/13/2024	$6.00 → $1.00	Buy → Hold	Stifel
6/13/2024	$10.00 → $1.00	Buy → Hold	Canaccord Genuity
6/13/2024		Buy → Hold	Needham
6/13/2024		Buy → Neutral	H.C. Wainwright
3/8/2023	$13.00 → $6.00	Neutral → Underperform	BofA Securities
3/8/2022	$17.00 → $20.00	Neutral → Overweight	JP Morgan
11/1/2021	$33.00	Buy	Canaccord Genuity
8/24/2021	$33.00 → $35.00	Buy	HC Wainwright & Co.

More analyst ratings

SEC Form SC 13G/A filed

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CARA

SEC Form SC 13G/A filed

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CARA

$CARA
FDA approvals

FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

$CARA
SEC Filings

Cara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Cara Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

$CARA
Analyst Ratings

$CARA
Insider Trading

Cara Therapeutics downgraded by Stifel with a new price target

Cara Therapeutics downgraded by Canaccord Genuity with a new price target

Cara Therapeutics downgraded by Needham

SEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin

SEC Form 4 filed by SVP, Research & Development Larson Jeffrey Leroy

SEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul

$CARA
Press Releases

Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics

Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split

Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

$CARA
Leadership Updates

Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

KemPharm Announces Appointment of Christopher Posner as New Independent Director

Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors

$CARA
Financials

Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

$CARA
Large Ownership Changes

SEC Form SC 13D filed by Cara Therapeutics Inc.